SNDX Earnings Date: Nov 2, 2026 (Estimated) — Syndax Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is SNDX's next earnings date?
Syndax Pharmaceuticals, Inc. (SNDX) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.49 on revenue of $81.7M.
How did SNDX do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Syndax Pharmaceuticals, Inc. posted EPS of -$0.55 versus the -$0.46 estimate, a miss of 19.6%. Revenue was $72.8M against a $79.9M estimate. The stock's 1-day post-earnings move was +4.4%.
How much does SNDX stock move after earnings?
SNDX beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.3% (up or down) in the day after earnings.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.46 | -0.55 | -19.57% | $72.8M | ❌ Miss | +4.40% | +6.34% | +8.91% |
| 2026-04-30 | Q1 2026 | -0.59 | -0.48 | +18.64% | $64.9M | ✅ Beat | -10.83% | -4.15% | -12.04% |
| 2026-02-26 | Q4 2025 | -0.60 | -0.78 | -30.00% | $68.7M | ❌ Miss | +5.03% | +4.40% | +13.64% |
| 2025-11-03 | Q3 2025 | -0.72 | -0.70 | +2.78% | $45.9M | ✅ Beat | +11.56% | +14.24% | +43.24% |
| 2025-08-04 | Q2 2025 | -1.00 | -0.83 | +16.16% | $38.0M | ✅ Beat | +21.10% | +20.52% | +55.40% |
| 2025-03-03 | Q4 2024 | -1.08 | -1.10 | -1.85% | $7.7M | ❌ Miss | -1.02% | -14.19% | -21.45% |
| 2024-11-05 | Q3 2024 | -1.11 | -0.98 | +11.71% | $12.5M | ✅ Beat | +8.43% | -17.67% | -14.68% |
| 2024-08-01 | Q2 2024 | -0.91 | -0.80 | +12.09% | $3.5M | ✅ Beat | -4.36% | -9.14% | -6.59% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $72.8M total
| Segment | Share | Revenue | YoY | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| Product | 75.1% | $54.7M | +91.3% | $32.0M | — | $48.9M | $54.7M |
| Collaboration revenue | 24.9% | $18.1M | +93.3% | $13.9M | $19.1M | $15.9M | $18.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.